1. Finch CA, Deubelbeiss K, Cook JD, Eschbach JW, Harker LA, Funk DD, Marsaglis G, Hillman RS, Slichter SJ, Adamson JW, Gansoni A, Giblett ER. Ferrokinetics in man. Medicine 48:17-53, 1970.

2. Harker LA, Slichter SJ: Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. New Engl J Med 283:1302-1305, 1970.

3. Thomas ED, Rudolph RH, Fefer A, Storb R, Slichter SJ, Buckner CD: Isogeneic marrow grafting in man. Exp Hematol 21:16-18, 1971.

4. Thomas ED, Buckner CD, Rudolph RH, Fefer A, Storb R, Neiman PE, Bryant JE, Chard RL, Clift RA, Epstein RB, Fialkow PJ, Funk DD, Giblett ER, Lerner KG, Reynolds FA, Slichter SJ. Allogeneic marrow grafting for hematologic malignancy using HLA-A matched donor-recipient sibling pairs. Blood 38:267-287, 1971.

5. Thomas ED, Bryant JE, Buckner CD, Clift RA, Fefer A, Fialkow PJ, Funk DD, Neiman PE, Rudolph RH, Slichter SJ, Storb R. Allogeneic marrow grafting using HL-A matched donor-recipient sibling pairs. Trans Assoc Am Physic 84:248-261, 1971.

6. Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Funk DD, Neiman PE, Slichter SJ, Storb R, Thomas ED. High dose cyclophosphamide therapy for malignant disease: Toxicity, tumor response and the effects of stored autologous marrow. Cancer 29:357-365, 1972.

7. Thomas ED, Storb R, Fefer A, Slichter SJ, Bryant JI, Buckner CD, Neiman PE, Clift RA, Funk DD, Lerner KE. Aplastic anemia treated by marrow transplantation. Lancet 1:284-289, 1972.

8. Harker LA, Slichter SJ: The bleeding time as a screening test for evaluating platelet function. New Engl J Med 287:155-159, 1972.

9. Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. New Engl J Med 287:999-1005, 1972.

10. Slichter SJ, Harker LA. Hemostasis in malignancy. Ann New York Acad Sci 230:252-261, 1974.

11. Slichter SJ, Funk DD, Leandoer LE, Harker LA. Kinetic evaluation of hemostasis during surgery and wound healing. Br J Haematol 27:115-125, 1974.

12. Harker LA, Slichter SJ. Arterial and venous thromboembolism: Kinetic characterization and evaluation of therapy. Thrombos Diathes 31:188-203, 1974.

13. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: Vascular injury and arterial thrombosis. New Engl J Med 291:537-543, 1974.

14. George CRP, Slichter SJ, Quadracci LJ, Striker GE, Harker LA. A kinetic evaluation of hemostasis in renal disease. New Engl J Med 291:1111-1115, 1974.

15. George CRP, Slichter SJ, Quadracci LJ, Kenny GM, Dennis MB, Striker GE, Harker LA. The treatment of rejection. A trial of acetylsalicylic acid, dipyridamole and heparin. Transplantation 20:237-240, 1975.

16. Slichter SJ, Harker LA: Platelet preparation and storage. Transfusion 16:8-12, 1976.

17. Weiden PL, Storb R, Slichter SJ, Warren RP, Sale GE. Effect of six weekly transfusions on canine marrow grafts: Tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 117:143-150, 1976.

18. Slichter SJ, Counts RB, Henderson R, Harker LA. Preparation of cryoprecipitated factor VIII concentrates. Transfusion 16:616-626, 1976.

19. Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol 34:395-402, 1976.

20. Slichter SJ, Harker LA: Preparation and storage of platelet concentrates. II. Storage variables influencing platelet viability and function. Br J Haematol 34:403-419, 1976.

21. Harker LA, Ross R, Slichter SJ, Scott CR, Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58:731-741, 1976.

22. Riella MC, George CRP, Hickman RO, Striker GE, Slichter SJ, Harker LA, Quadracci LJ. Renal microangiopathy of the hemolytic-uremic syndrome in childhood. Nephron 17:188-203, 1976.

23. Harker LA, Hanson SR, Slichter SJ. Platelet kinetic evaluation of prosthetic material in vivo. Ann New York Acad Sci 283:317-329, 1977.

24. Harker LA, Slichter SJ, Sauvage LR: Platelet consumption by arterial prostheses: The effects of endothelialization and pharmacologic inhibition of platelet function. Ann Surg 186:594-601, 1977.

25. Slichter SJ. Efficacy of platelets collected by semi-continuous flow centrifugation (Haemonetics Model 30). Br J Haematol 38:131-140, 1978.

26. Slichter SJ, Harker LA. Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin Haematol 7:523-539, 1978.

27. Weiden PL, Slichter SJ, Banaji M. Marrow transplantation for aplastic anemia and leukemia -- Review of results and blood product support required. Prog Clin Biol Res 28:295-312, 1978.

28. Slichter SJ. Preservation of platelet viability and function during storage of concentrates. Prog Clin Biol Res 28:83-100, 1978.

29. Slichter SJ. Selection of compatible platelet donors. In, Platelet Physiology and Transfusion; pgs. 83-92. American Association of Blood Banks: Washington, D.C. 1978.

30. Storb R, Deeg HJ, Weiden PL, Graham TC, Atkinson KA, Slichter SJ, Thomas ED. Marrow graft rejection in DLA identical canine littermates: Antigens involved are expressed on leukocytes and skin epithelial cells but probably not on platelets and red blood cells. Transplant Proc 11:504-506, 1979.

31. Storb R, Weiden PL, Deeg HJ, Graham TC, Atkinson K, Slichter SJ, Thomas ED. Rejection of marrow from DLA identical canine littermates given transfusions before grafting: Antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. Blood 54:477-484, 1979.

32. Feusner JH, Slichter SJ, Harker LA. Mechanisms of thrombocytopenia in varicella. Am J Hematol 7:255-264, 1979.

33. Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ. The Wiskott-Aldrich syndrome: Characterization of the lymphocyte, granulocyte and platelet defects. Blood 55:243-252, 1980.

34. Glowitz RJ, Slichter SJ. Frequent multiunit plateletpheresis from single donors: Effects on donors' blood and the platelet yield. Transfusion 20:199-205, 1980.

35. Slichter SJ: Controversies in platelet transfusion therapy. Ann R Med 31:509-540, 1980.

36. Scott EP, Slichter SJ. Viability and function of platelet concentrates stored in CPD-adenine (CPDA-1). Transfusion 20:489-497, 1980.

37. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective a granule release. Blood 56:824-834, 1980.

38. Slichter SJ. Bleeding disorders secondary to platelet abnormalities. In, Current Therapy; pgs. 287-293. HF Conn, Philadelphia. 1981.

39. O'Donnell MR, Slichter SJ, Weiden PL, Storb R. Platelet and fibrinogen kinetics in canine tumors. Cancer Res 41:1379-1383, 1981.

40. Aster RH, Jenkins WJ, Tovey LA, Kahn RA, Katz AJ, Muller-Berghaus G, Prins HK, Loos JA, Schiffer CA, Slichter SJ. Which are the parameters to be controlled in platelet concentrates in order that they may be offered to the medical profession as a standardized product with specific properties? Vox Sang 40:115-125, 1982.

41. Slichter SJ: Platelet crossmatch testing for donor selection. In, WR Vogler (ed.), Cytapheresis and Plasma Exchange; pgs. 153-164. Alan R. Liss, Inc.: New York, NY. 1982.

42. Slichter SJ. In vitro measurements of 4oC and 22oC stored platelet concentrates: Correlation with post-transfusion platelet viability and function. Vox Sang 40(Suppl. 1):72-86, 1981.

43. Feusner JH, Slichter SJ, Harker LA. Acquired haemostatic defects in the ill newborn. Br J Haematol 53:73-84, 1983.

44. Slichter SJ, Stegall P, Smith K, Huang TW, Harker LA. Dysbaric osteonecrosis: A consequence of intravascular bubble formation, endothelial damage and platelet thrombosis. J Lab Clin Med 98:568-590, 1981.

45. Lane J, Brown M, Bernstein I, Wilcox PK, Slichter SJ, Nowinski R. Serological and biochemical analysis of the PLA1 alloantigen of human platelets. Br J Haematol 50:351-359, 1982.

46. Slichter SJ. Post-transfusion purpura: Response to steroids and association with red blood cell and lymphocytotoxic antibodies. Br J Haematol 50:599-605, 1982.

47. Schwartz KA, Slichter SJ, Harker LA. Immune-mediated platelet destruction and thrombocytopenia in patients with solid tumors. Br J Haematol 51:17-24, 1982.

48. Slichter SJ, Weiden PL, O'Donnell MR, Storb R. Interruption of tumor associated platelet consumption with platelet enzyme inhibitors. Blood 59:1252-1258, 1982.

49. Slichter SJ. Identification and management of defects in platelet hemostasis in massively transfused patients. Prog Clin Biol Res 108:225-258, 1982.

50. Schiffer CA, Slichter SJ. Sounding board. Platelet transfusions from single donors. New Engl J Med 307:245-248, 1982.

51. Slichter SJ: Indications for platelet transfusions. Plasma Therapy 3:259-264, 1982.

52. Lindberg JE, Slichter SJ, Murphy S, Schroeder DD, Nelson EJ, Champion AB, Carmen RA. In vitro function and in vivo viability of stored platelet concentrates. Effect of a secondary plasticizer component of PVC storage bags. Transfusion 23:294-299, 1983.

53. Slichter SJ. Platelet transfusion. In, M Brain, P McCullough (eds.), Current Therapy in Hematology-Oncology; pgs. 282-287. B.C. Decker, Inc.: Burlington, Ontario. 1983.

54. Slichter SJ. Initial Management of Bleeding Secondary to Platelet Abnormalities. In, RF Edlich, DA Spyker (eds.), Emergency Medical Therapy - 1984. Appleton-Century-Crofts, 1985.

55. Malpass TW, Savage B, Hanson SR, Slichter SJ, Harker LA. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med 103:894-904, 1984.

56. Meyer DM, Hillman RS, Slichter SJ. Plateletapheresis program: I. Donor recruitment and commitment. Transfusion 24:287-291, 1984.

57. Jorgensen DW, McFarland JG, Hillman RS, Slichter SJ. Plateletapheresis program: II. Computer selection of HLA compatible donors. Transfusion 24:292-298, 1984.

58. Gjerset GF, Slichter SJ, Hansen JA. HLA, blood transfusion and the immune system. Clinics in Immunology and Allergy 4:495, 1984.

59. Loughran TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche CC, Lum LG, Slichter SJ. Leukemia of large granular lymphocytes: Association with clonal chromosomal abnormalities and autoimmune netropenia, thrombocytopenia, and hemolytic anemia. Ann Int Med 102:169-175, 1985.

60. Slichter SJ. Optimum platelet concentrate preparation and storage. In, G Garratty (ed.), Current Concepts in Transfusion Therapy. American Association of Blood Banks: Arlington, VA. 1985.

61. Slichter SJ. Prevention of platelet alloimmunization. Prog Clin Biol Res 211:83-116, 1986.

62. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood 66:1105-1109, 1985.

63. McFarland JG, Larson EB, Hillman RS, Slichter SJ. Cost-benefit analysis of a plateletapheresis program. Transfusion 26:91-97, 1986.

64. Slichter SJ. Post-storage platelet viability in thrombocytopenic patients is reliably measured by radiochromium labelled platelet recovery and survival measurements in normal volunteers. Transfusion 26:8-13, 1986.

65. Banaji M, Bearman SI, Buckner CD, Clift RA, Bensinger WI, Peterson FB, Slichter SJ, McGuffin RW, Sanders JE, Stewart PS, Hill RS, Deeg HJ, Storb R, Thomas ED. The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow tranplantation. Am J Hematol 22:275-283, 1986.

66. Segal GM, Ballem P, Gernsheimer T, Slichter SJ, Adamson JW. Autoimmune thrombocytopenia: Progenitor cell response to platelet demand. Prog Clin Biol Res 215:341-345, 1986.

67. Slichter SJ, O'Donnell MR, Weiden PL, Storb R, Schroeder ML. Canine platelet alloimmunization: The role of donor selection. Br J Haematol 63:713-727, 1986.

68. Bensinger WI, Buckner CD, Clift RA, Slichter SJ, Thomas ED. Plasma exchange for platelet alloimmunization. Transplantation 41:602-605, 1986.

69. Osborne WRA, Deeg HJ, Slichter SJ. A canine model of induced purine nucleoside phosphorylase deficiency. Clin Exp Immunol 66:166-172, 1986.

70. Slichter SJ, Deeg HJ, Kennedy MS. Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporine-loading of donor platelets. Blood 69:414-418, 1987.

71. Slichter SJ. Mechanisms of refractoriness to transfused platelets. J Japan Soc Blood Transfus 32:557-558, 1986.

72. Slichter SJ. Prevention of platelet alloimmunization. J Japan Soc Blood Transfus 32:611-613, 1986.

73. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 80:33-40, 1987.

74. Klingemann HG, Self S, Banaji M, Deeg HJ, Doney K, Slichter SJ, Thomas ED, Storb R. Refractoriness to random donor platelet transfusions in patients with aplastic anemia: A multivariate analysis of data from 264 cases. Br J Haematol 66:115-121, 1987.

75. Slichter SJ. Practical aspects of platelet concentrate production and storage. In, CTS Sibinga (ed.), White Cells and Platelets in Blood Transfusion: Proceedings of 1986 Red Cross Blood Bank Groningen Symposium on Blood Transfusion. The Netherlands. 1987.

76. Deeg HJ, Slichter SJ, Storb R. Transfusion-induced allosensitization in marrow transplant recipients: Mechanisms and preventive measures. In, SJ Baum (ed.), Experimental Hematology Today-1987; pgs. 18-23. Springer Verlag: New York. 1988.

77. Slichter SJ. Transfusion and bone marrow transplantation. Transfusion Med Rev 2:1-17, 1988.

78. Slichter SJ, Weiden P, Kane P, Storb R. Approaches to preventing or reversing platelet alloimmunization using animal models. Transfusion 28:103-108, 1988.

79. Stratton JR, Ballem PJ, Gernsheimer T, Cerqueira M, Slichter SJ. Platelet destruction in autoimmune thrombocytopenic purpura: Quantitation of platelet kinetics and sites of clearance using Indium-111 labeled autologous platelets. J Nucl Med 30:629, 1989.

80. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-versus-host disease is associated with autoimmune-like thrombocytopenia. Blood 73:1054-1058, 1989.

81. McFarland JG, Anderson AJ, Slichter SJ. Factors influencing the response to HLA-selected apheresis platelets in patients refractory to random platelet concentrates. Br J Haematol 73:380-386, 1989.

82. Bolgiano DC, Larson EB, Slichter SJ. Donor pool size considerations and ability to provide HLA-matched pheresis transfusions to alloimmunized thrombocytopenic patients. Transfusion 29:306-310, 1989.

83. Gernsheimer TB, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of treatment responses in autoimmune thrombocytopenic purpura (AITP). New Engl J Med 320:974-980, 1989.

84. Bensinger WI, Peterson FB, Banaji M, Buckner CD, Clift R, Slichter SJ, Storb R, Thomas ED. Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission. Bone Marrow Transplant 4:409-414, 1989.

85. Welch HG, Larson EB, Slichter SJ. Providing platelets for refractory patients: Prudent strategies. Editorial. Transfusion 29:193-195, 1989.

86. Slichter SJ. Transfusion support in bone marrow transplantation. In, E Rossi, T Simon, G Moss (eds.), Principles of Transfusion Medicine; pgs. 511-519. Williams & Wilkins: Baltimore, MD. 1990.

87. Slichter SJ, Osborne WRA, Deeg HJ. Inhibition of purine nucleoside phosphorylase (PNP) impairs platelet alloimmunization in a dog model. Br J Haematol 75:591-597, 1990.

88. Beatty PG, Atcher C, Hess E, Meyer DM, Slichter SJ. Recruiting blood donors into a local bone marrow donor registry. Transfusion 29:778-782, 1989.

89. Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 4:291-311, 1990.

90. Slichter SJ. Principles of platelet transfusion therapy. In, E Benz, H Cohen, B Furie, R Hoffman, S Shattil (eds.), Hematology: Basic Principles and Practice; pgs. 1610-1622. Churchill Livingstone, Inc.: New York, NY. 1991.

91. Bensinger WI, Hadlock J, Slichter SJ. Identification of alloimmunized patients: Use of radiolabeled allogeneic platelet kinetic measurements and platelet antibody tests. Blood 77:2372-2378, 1991.

92. Larson EB, Chestnut T, Slichter SJ. The first year costs of establishing an unrelated marrow registry. Transfusion 30:138-141, 1990.

93. Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ, Shulman HM, McDonald GB. A pilot study of continuous infusion heparin for the prevention of hepatic venoocclusive disease after bone marrow transplantation. Bone Marrow Transplant 5:407-411, 1990.

94. Slichter SJ. Mechanisms and management of platelet refractoriness. In, SJ Nance (ed.), Transfusion Medicine In the 1990's; pgs. 95-179. American Association of Blood Banks: Arlington, VA. 1990.

95. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cyto­megalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78:246-250, 1991.

96. Slichter SJ. UV irradiation: Effects on the immune system and on platelet function, viability, and alloimmunization. In, CTh. Smit Sibinga, L Kater (eds.), Advanced in Haemapheresis. Proceedings of the Third International Congress of the World Apheresis Association; April, 1990; Amsterdam, The Netherlands. Kluwer Academic Publishers: Dordrecht, The Netherlands, 1991.

97. Nash RA, Schuening F, Appelbaum F, Hammond WP, Boone T, Morris CF, Slichter SJ, Storb R. Molecular cloning and in vivo evaluation of canine GM-CSF. Blood 78:930-937, 1991.

98. Slichter SJ. Platelet transfusions -- A constantly evolving therapy. Thromb Haemost 66(1):178-188, 1991.

99. Slichter SJ. Platelet alloimmunization. In, KC Anderson, P Ness (eds.), Scientific Basis of Transfusion Medicine, pgs. 527-543. WB Saunders Company: Orlando, FL. 1994.

100. Slichter SJ. Alloimmune refractoriness to transfused platelets. In, G Garratty (ed.), Immunology Of Transfusion Medicine, pgs. 597-627. M Dekker, Inc.: New York, NY. 1994.

101. Slichter SJ. Principles of Transfusion Support For Bone Marrow Transplant Patients. In, SJ Forman, KG Blume, ED Thomas (eds.), Bone Marrow Transplantation, pgs. 273-298. Blackwell Scientific Publications, Inc.: Cambridge, MA. 1994.

102. Slichter SJ. An analysis of platelet preparation and storage conditions and their effects on “in vivo” post-transfusion platelet viability in normal volunteers and thrombocytopenic patients. Yale Transfusion Medicine Symposium On The Cellular and Molecular Basis Of The Platelet Storage Lesion. April, 1991, Bethesda, MD.

103. Sarason I, Sarason BR, Slichter SJ, Beatty PG, Meyer DM, Bolgiano DC. Increasing participation in a bone marrow registry. Health Psychol 12:272-276, 1993.

104. Bolgiano DC, Smith S, Slichter SJ. Strategies to recruit platelet apheresis donors from among members of an HLA-typed unrelated bone marrow donor registry. Transfusion 33:675-678, 1993.

105. Meyer D, Bolgiano DC, Sayers M, Price T, Benson D, Slichter SJ. Red blood cell collection by apheresis technology. Transfusion 33:819-824, 1993.

106. Slichter SJ. Platelet transfusions as replacement therapy. Triangle 32(2):71-84, 1993.

107. Reiner AP, Teramura G, Nelson K, Slichter SJ. A platelet monoclonal antibody inhibi­tion assay for detection of glycoprotein IIb/IIIa-related platelet alloantibodies. J Immunol Meth 184:153-162, 1995.

108. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 86:3598-3603, 1995.

109. Nash RA, Seidel K, Storb R, Slichter S, Schuening FG, Appelbaum FR, Becker AB, Bolles L, Deeg HJ, Graham T, Hackman R, Burstein SA. Effects of recombinant human Interleukin-11 on normal dogs and after sublethal radiation. Experimental Hematol 23:389-396, 1995.

110. Lee TH, Donegan E, Slichter S, Busch MP. Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 85:1207-1214, 1995.

111. Kao KJ, Mickel M, Braine HG, Davis K, Enright H, Gernsheimer T, Gillespie MJ, Kickler TS, Lee EJ, McCullough JJ, McFarland JG, Nemo GJ, Noyes WD, Schiffer CA, Sell K, Slichter SJ, Woodson RD, and The TRAP Study Group. White cell reduction in platelet concentrates and packed red blood cells by filtration: A multicenter clinical trial. Transfusion 35:13-19, 1995.

112. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 85:351-358, 1995.

113. Slichter SJ. Principles of platelet transfusion therapy. In, R Hoffman, EJ Benz, SJ Shattil, B Furie, HJ Cohen, LE Silberstein (eds.), Hematology: Basic Principles and Practice (Second Edition); pgs. 1987-2006. Churchill Livingstone, Inc.: New York, NY. 1995.

114. Slichter SJ. Transfusion support in bone marrow transplantation. In, EC Rossi, TL Simon, GS Moss, SA Gould (eds.), Principles of Transfusion Medicine (Second Edition); pgs. 521-535. Williams & Wilkins: Baltimore, MD. 1996.

115. Teramura G, Slichter SJ. Report on the Sixth International Society of Blood Transfusion Platelet Serology Workshop. Transfusion 36:75-81, 1996.

116. Nash RA, Burstein SA, Storb R, Yang W, Abrams K, Appelbaum FR, Boone T, Deeg HJ, Durack LD, Schuening FG, McDonough S, Moore P, Nelp WB, Slichter SJ. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets. Blood 86:1765-1775, 1995.

117. Slichter SJ. Platelet production, physiology, hemostasis, and transfusion therapy. In, BD Spiess, SA Gould, RB Counts (eds.), Perioperative Transfusion Medicine; pgs. 61-77. Williams & Wilkins: Baltimore, MD. 1998.118. Slichter, SJ. An algorithm for managing the platelet refractory patient. J Clin Apheresis 12:4-9, 1997.

119. The Trial To Reduce Alloimmunization To Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337:1861-1869, 1997.

120. Dale DC, Nichol JL, Rich DA, Best DM, Slichter SJ, Sheridan W, Hunt P. Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand. Blood 90:3456-3461, 1997.

121. Slichter SJ. Optimizing platelet transfusions in chronically thrombocytopenic patients. Semin Hematol 35:269-278, 1998.

122. Slichter SJ. Platelet refractoriness and alloimmunization. Leukemia 12(Suppl 1):S51-S53, 1998.

123. Dumont LJ, VandenBroeke T, Ault KA, and the members of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Platelet surface P-selectin measurements in platelet preparations: An international collaborative study. Transfus Med Rev 13:31-42, 1999.

124. Davis KB, Slichter SJ, Corash L. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: Problems and a solution. Transfusion 39:586-592, 1999.

125. Dzik S, AuBuchon J, Jeffries L, Kleinman S, Manno C, Murphy MF, Popovsky MA, Sayers M, Silberstein LE, Slichter SJ, Vamvakas EC. Leukocyte reduction of blood components: Public policy and new technology. Tranfus Med Rev 14:34-52, 2000.

126. Thurer RL, Luban NLC, AuBuchon JP, Silver H, McCarthy LJ, Dzik S, Stowell CP, Moore SB, Vamvakas EC, Armstrong W, Kanter MH, Jeter E, Becker J, Higgins M, Galel S, Kleinman S, Marshall CS, Newman R, Ocariz JA, Blackall D, Petz LD, Toy P, Oberman H, Siegel DL, Price TH, Slichter SJ. Universal WBC reduction. Transfusion 40:751-752, 2000.

127. Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, Peterson, R, Price T, Smith K, Tomita D, Armstrong S. Prophylactic platelet transfusions from normal apheresis donors treated with Pegylated Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF). Blood 98(5):1346-1351, 2001.

128. Nash RA, Takatu A, Feng Z, Slichter S, Abrams K, Espino G, Gass MJ, Georges GE, Hart C, McSweeney PA, Shulman HM, Storb, R. Effect of c-mpl ligands after total body irradiation with and without allogeneic hematopoietic stem cell transplantation: Low-dose total body irradiation does not prevent sensitization. Biol Blood Marrow Transplantation 8(7):360-367, 2002.

129. Slichter SJ. Understanding the effects of different types of white cells on patient’s responses to transfusion: immunization versus tolerizaton. Vox Sang 83(Suppl 1):421-424, 2002.

130. Abrams K, Yunusov MY, Slichter SJ, Moore P, Nelp WB, Burstein SA, McDonough S, Durack L, Storer B, Storb R, Gass MJ, Georges G, Nash RA. Recombinant human macrophage colony-stimulating factor induced thrombocytopenia in dogs. Br J Haematol 121(4):614-622, 2003.

131. Enright H, Davis K, Gernsheimer T, McCullough JJ, Woodson R, Slichter SJ. Factors influencing moderate to severe reactions to platelet transfusions: Experience of the TRAP multicenter clinical trial. Transfusion 43(11):1545-1552, 2003.

132. Gulliksson H, AuBuchon JP, Cardigan R, van der Meer PF, Murphy S, Prowse C, Richter E, Ringwald J, Smacchia C, Slichter S, de Wildt-Eggen J for the Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Storage of platelets in additive solutions: A multi-center study of the effects of potassium and magnesium. Vox Sang 85(3):199-205, 2003.

133. Slichter SJ. Platelet transfusion: Future directions. Vox Sang 87(Suppl 2):S47-S51, 2004.

134. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Trans Med Rev 18(3):153-167, 2004.

135. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT trial. Blood 104(5):1534-1541, 2004.

136. Slichter SJ, Fish D, Abrams VK, Gaur L, Nelson K, Bolgiano D. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model. Blood 105(2):847-854, 2005.

137. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer C, Woodson R. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105(10):4106-4114, 2005.

138. Heddle NM, Cook RJ, Sigouin C, Slichter SJ, Murphy M, Rebulla P. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion, in press.

139. AuBuchon JP, Herschel L, Roger J, Dumont L, Murphy S, Slichter SJ, Whitley P, Snyder E, Goodrich RP. Comparison of computerized formulae for determination of platelet recovery and survival. (Letter) Transfusion 45(7):1237-1238, 2005.

140. Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, Lin J-S, Corash, L, Conlan MG for the SPRINT Study Group. The SPRINT Trial: Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: An analysis of the SPRINT Trial of platelets photochemically treated with Amotosalen HCl and ultraviolet A light. Transfusion 46(1):24-33, 2006.

141. Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apheresis 21(1):78-84, 2006.

142. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin J-S, Corash L, Conlan MG for the SPRINT Study Group. Clinical safety of platelets photochemically treated with Amotosalen HCl and ultraviolet A light for pathogen inactivation: Results of the SPRINT Trial. Transfusion 45(12):1864-1875, 2005.

143. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash, L, Conlan MG. Platelets photochemically-treated with amotosalen HCL and ultraviolet A light correct prolonged bleeding times in thrombocytopenic patients. Transfusion, in press.

144. Dumont LJ, AuBuchon JP, Gulliksson H, Slichter SJ, Elfath MD, Holme S, Murphy JR, Rose L, Popovsky M, Murphy S. In vitro pH effects on in vivo recovery and survival of platelets – A meta-analysis by the BEST collaborative. Transfusion, in press.

145. Slichter SJ, Bolgiano D, Jones MK, Christoffel T, Corson J, Rose L, Foley J, Popovsky M, Baril L, Corda T, Dincecco D, Snyder EL. Viability and function of 8-day stored apheresis platelets. Transfusion, in press.

146. Slichter SJ. Prophylactic platelet transfusion therapy. Transfus Med Rev, in press.

147. Slichter SJ, AuBuchon JP, Bolgiano D, Snyder EL, Whitley P. Investigating the basis and application of acceptability criteria for stored platelets. Transfusion, in press.